We subsequently analyzed the patient samples along with the IQC samples at the same time, and the IQC results were also under control, suggesting that the BCR-ABL P210 results of the CML patients were stable and credible (Figures 1A–C). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.